Table 2.
Characteristic of cytomegalovirus seropositive participants stratified by negative versus positive total plaque volume.
| Characteristic | TPV = 0 (n = 55) | TPV > 0 (n = 109) | P value |
|---|---|---|---|
| AdapNK cells expansion frequency, n (%) | |||
| High | 32 (58.18) | 42 (38.53) | .01 |
| Intermediate | 19 (34.54) | 42 (38.53) | |
| Low | 4 (7.27) | 25 (22.93) | |
| Sex, n (%) | |||
| Males | 52 (94.5) | 97 (88.9) | .24 |
| Females | 3 (5.5) | 12 (11.0) | |
| Age (yr) median, IQR | 54.6 (50.4–58.6) | 57.3 (52.7–62.6) | .006 |
| Hypertension, n (%) | 15 (27.3) | 32 (29.4) | .59 |
| Diabetes mellitus, n (%) | 1 (1.8) | 11 (10.0) | .06 |
| HDL cholesterol (mmol/L) median (IQR) |
46 (83.6) 1.3 (1.02–1.49) |
105 (96.3) 1.27 (1.07–1.47) |
.57 |
| LDL cholesterol (mmol/L) median (IQR) |
44 (80) 2.9 (2.5–3.6) |
104 (95.4) 2.2 (2.2–3.5) |
.56 |
| Markers of inflammation, n (%) | |||
| D-dimer (ng/mL) median (IQR) |
12 (21.8) 200.5 (170–282.8) |
47 (41.9) 303 (269–410) |
.004 |
| Hs-CRP (mg/L) median (IQR) |
30 (54.5) 5 (5–5) |
77 (68.8) 5 (5–5) |
.09 |
| Lipid-lowering medication use, n (%) | |||
| Statin | 11 (20) | 35 (32.1) | .09 |
| Anti-platelet | 5 (9.1) | 24 (22.0) | .09 |
| Smoking exposure (packs/yr), n (%) | |||
| Smokers median (IQR) |
32 (58.1) 6.0 (3.5–25.5) |
73 (66.9) 20.0 (7.7–33.0) |
.002 |
| Nonsmokers median (IQR) |
20 (36.3) 0 (0–0) |
28 (25.7) 0 (0–0) |
|
| Physically active, n (%) | |||
| Yes | 29 (52.7) | 41 (37.6) | .06 |
| No | 25 (45.5) | 67 (61.4) | |
| BMI (kg/m2), n (%) | 51 (92.9) 26.2 (23.1–27.9) |
107 (98.1) 24.2 (22.1–29.2) |
.27 |
| Waist circumference (cm), n (%) median (IQR) |
51 (92.7) 93.0 (89.0–100.0) |
107 (98.2) 92.0 (86.0–101.0) |
.53 |
P values considered significant are shown in bold.
AdapNK cells = adaptive NK cells, BMI = body mass index., HDL = high-density lipoprotein cholesterol, Hs-CRP = high sensitivity C-reactive protein, IQR = interquartile range, LDL = low-density lipoprotein cholesterol, TPV = 0 = negative for subclinical atherosclerosis, TPV > 0 = positive for subclinical atherosclerosis.